24.9 C
New York
Wednesday, June 3, 2026

Tag: media relations

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting

Assemblée Générale Mixte du 24 juin 2026 Modalités de mise à disposition des documents préparatoires à l’Assemblée

Afreximbank Deepens Commitment to Economic Progress in The Bahamas

The roadshow which took place under the theme "Investing in progress through the implementation of the Afreximbank mandate in The Bahamas" built on the...

Equinor ASA: Share buy-back – second tranche for 2026

Please see below information about transactions made under the second tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Equinor ASA: Tilbakekjøp av egne aksjer – andre transje for 2026

Nedenfor følger informasjon om transaksjoner foretatt under andre transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2026.

GAINS Positioned as the Leader in the 2026 SPARK Matrix™ for Supply Chain Network Design (SCND) by QKS Group

The QKS Group SPARK Matrix™ provides competitive analysis and ranking of the leading Supply Chain Network Design vendors.GAINS, with its comprehensive technology for SCND,...

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and...

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

PIMCO Canada Corp. Announces Monthly Distributions for PIMCO Canada Exchange Traded Series

Not for distribution to United States newswire services or for dissemination in the United States

Cingulate Provides Management Team Update

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

Course of Extraordinary General Meeting

On 14 August 2025 an Extraordinary General Meeting in Pandora A/S was held.

Old National Bancorp Announces Quarterly Dividends

EVANSVILLE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ONB) Old National Bancorp (the “Company” or “Old National”) today announced that its Board of Directors declared a quarterly cash dividend of $0.14 per share on the Company’s outstanding shares of common stock. This quarterly cash dividend will be payable on September 15, 2025, to shareholders of record as of the close of business on September 5, 2025.

Gap Inc. Announces Third Quarter Dividend

SAN FRANCISCO, Aug. 13, 2025 /PRNewswire/ -- Gap Inc. (NYSE: GAP) today announced that its board of directors has authorized a third quarter fiscal year...

/R E P E A T — MEDIA ADVISORY – Government of Canada to announce site for new Cultural Heritage Science facility/

GATINEAU, QC, Aug. 12, 2025 /CNW/ - The Honourable Joël Lightbound, Minister of Government Transformation, Public Works and Procurement, will announce the site for a...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedia relations